Atypical presentation of therapy-related acute promyelocytic leukaemia with marrow fibrosis

Pathology. 2016 Apr;48(3):286-8. doi: 10.1016/j.pathol.2016.02.012. Epub 2016 Mar 9.

Authors

Muhajir Mohamed¹, Harry J Iland², Sharad Sharma³, Shane G Supple⁴

Affiliations

¹ Launceston General Hospital, Launceston, Australia; University of Tasmania, Launceston, Tas, Australia. Electronic address: muhajirbm@yahoo.com.
² Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia.
³ Launceston General Hospital, Launceston, Australia.
⁴ Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

PMID: 27020510
DOI: 10.1016/j.pathol.2016.02.012

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Disease
Adenocarcinoma / drug therapy*
Adenocarcinoma / therapy
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Capecitabine / adverse effects
Capecitabine / therapeutic use
Chemoradiotherapy
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / therapy
Female
Humans
Idarubicin / therapeutic use
Leukemia, Promyelocytic, Acute / diagnosis*
Leukemia, Promyelocytic, Acute / drug therapy
Leukemia, Promyelocytic, Acute / etiology
Leukemia, Promyelocytic, Acute / pathology
Middle Aged
Neoplasms, Second Primary / diagnosis*
Neoplasms, Second Primary / drug therapy
Neoplasms, Second Primary / etiology
Neoplasms, Second Primary / pathology
Organoplatinum Compounds / adverse effects
Organoplatinum Compounds / therapeutic use
Oxaliplatin
Pancytopenia
Primary Myelofibrosis / diagnosis*
Primary Myelofibrosis / drug therapy
Primary Myelofibrosis / etiology
Primary Myelofibrosis / pathology
Remission Induction
Tretinoin / therapeutic use

Substances

Antineoplastic Agents
Organoplatinum Compounds
Oxaliplatin
Tretinoin
Capecitabine
Idarubicin